SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts. The inaugural members of the SAB include Alterome co-founder Ryan Corcoran, M.D., Ph.D., Benjamin Cravatt, Ph.D., Paul Workman, Ph.D., and Keith Flaherty, M.D. The SAB will work closely with the Alterome management team to provide scientific and clinical guidance as the company advances its initial pipeline programs into the clinic.
“We are proud to have such a strong team of advisors, whose leadership in oncology drug development spans the mechanistic drivers of cancer, biomarker-led drug discovery, personalized cancer medicine, and clinical cancer research,” said Eric Murphy, Ph.D., co-founder, CEO and CSO of Alterome Therapeutics. “This rare combination of research and clinical expertise will be integral to advance Alterome’s pipeline of next-generation precision oncology programs.”
“I’m thrilled to be working with this exceptional group of renowned oncology experts to support Alterome’s efforts to deliver on our shared mission to develop alteration-specific therapies for individuals with genomically-defined cancers,” said Ryan Corcoran, M.D., Ph.D., chair of Alterome’s SAB. “While the oncology drug development community has made great strides in bringing novel therapies to patients, there remains a broad opportunity to create safer, efficacious treatments for cancers with genomically-defined drivers. I believe the experienced team at Alterome is well positioned to create truly transformative therapies for patients who need them.”
Alterome SAB Members:
Ryan Corcoran, M.D., Ph.D. (Chair) – Dr. Ryan Corcoran, a co-founder of Alterome, is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School. Dr. Corcoran directs a research laboratory focused on personalized cancer medicine: the development of therapeutic strategies that target the specific mutations driving individual patients’ tumors. His work focuses on understanding the molecular determinants of response or resistance to anti-cancer therapies. Dr. Corcoran’s laboratory is also studying new ways to utilize liquid biopsy, and specifically the analysis of circulating tumor DNA, in the clinic to optimize how we deliver cancer care to individual patients. Dr. Corcoran is a member of the National Cancer Institute GI Steering Committee, and an elected member of the American Society for Clinical Investigation (ASCI).
Benjamin Cravatt, Ph.D. – Benjamin F. Cravatt, Ph.D., is the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has a particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
Paul Workman, Ph.D. – Paul Workman is Harrap Professor of Pharmacology and Therapeutics at the Institute of Cancer Research, London (ICR). He is renowned for his research on the discovery and mechanistic investigation of cancer drugs and chemical probes and originated the concept of the Pharmacological Audit Trail for biomarker-led drug discovery and development. Paul is an elected Fellow of the Royal Society, Royal Society of Biology, Royal Society of Chemistry, Academy of Medical Sciences, and the European Academy of Cancer Sciences. Paul is the recipient of numerous honorary degrees and awards, including the CRUK Translational Research Prize and the AACR Team Science Award (Team Leader). Paul previously served as Chief Executive of the ICR (2014-2021), was Deputy Chief Executive of ICR (2011-2014); and Director of the ICR’s CRUK Cancer Therapeutics Unit, where he led the discovery of twenty drug candidates, twelve of which have progressed to clinical trials; and was Founding Director of the CRUK Convergence Science Centre at ICR and Imperial College and its predecessor (2016-2020). Paul was a co-founder of Chroma Therapeutics and Piramed Pharma (acquired by Roche); is a Science Partner at Nextech Invest; and is an adviser to several biotechnology companies. He is also Executive Director of the non-profit Chemical Probes Portal.
Keith Flaherty, M.D. – Dr. Keith Flaherty is the Director of Clinical Research at the Massachusetts General Hospital Cancer Center. He has served as Principal Investigator for numerous first-in-human clinical trials with novel, targeted therapies, including those of the first prospectively developed selective BRAF inhibitors for metastatic melanoma and has published more than 300 peer-reviewed papers. He is the principal investigator of the National Cancer Institute (NCI) MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. He serves as ECOG Deputy Chair for Biomarker Science. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors in 2019. He serves as editor-in-chief of Clinical Cancer Research.
About Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is led by an expert team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.
For more information, visit www.alterome.com.
